ACELYRIN, INC. Common Stock (SLRN NASDAQ) stock market data APIs
$2.4593
-0.07(-2.8%)
as of March 26, 2025
ACELYRIN, INC. Common Stock Financial Data Overview
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R for the treatment of Thyroid Eye Disease (TED), which is in Phase 2. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Prev. Close
2.5293
Open
2.4593
High
2.5945
Low
2.4278
52 wk Range
1.845-7.25
Market Cap
256 M
Shares Outstanding
101 M
EPS
-0.79
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ACELYRIN, INC. Common Stock data using free add-ons & libraries
Get ACELYRIN, INC. Common Stock Fundamental Data
ACELYRIN, INC. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -293 040 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-12-31
- EPS/Forecast: -0.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ACELYRIN, INC. Common Stock News
New
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their co...
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, ...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, TGI, PTMN, SLRN on Behalf of Shareholders
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or bre...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
